Insider Trades
News
globenewswire.comData at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systemsglobenewswire.comJun 5
globenewswire.comData at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systemsglobenewswire.comJun 5
globenewswire.comMannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPFglobenewswire.comJun 3
seekingalpha.comMannKind At An Inflection Point: Pediatric Expansion Drives The Storyseekingalpha.comJun 2
marketbeat.comMannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Marketmarketbeat.comMay 30